Roche (OTCMKTS:RHHBY) Rating Lowered to Hold at UBS Group

Roche (OTCMKTS:RHHBY) was downgraded by investment analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

A number of other research analysts have also issued reports on the company. Zacks Research upgraded Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Oddo Bhf upgraded Roche to an “outperform” rating in a research note on Tuesday, October 20th. Deutsche Bank Aktiengesellschaft raised Roche from a “hold” rating to a “buy” rating in a research report on Friday, October 23rd. Royal Bank Of Canada assumed coverage on shares of Roche in a research note on Tuesday, September 8th. They set an “outperform” rating on the stock. Finally, Morgan Stanley raised shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price on the stock in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Roche has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Roche Stock Performance

Roche stock opened at $59.18 on Monday. Roche has a twelve month low of $40.25 and a twelve month high of $61.49. The stock’s fifty day simple moving average is $55.70 and its 200-day simple moving average is $53.80. The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 0.69.

Hedge Funds Weigh In On Roche

Several hedge funds have recently added to or reduced their stakes in the stock. S&CO Inc. grew its position in shares of Roche by 163.0% in the 1st quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after buying an additional 87,107 shares during the last quarter. Opal Capital LLC purchased a new position in shares of Roche during the first quarter worth about $4,448,000. GAMMA Investing LLC increased its position in shares of Roche by 15.3% during the third quarter. GAMMA Investing LLC now owns 33,458 shares of the company’s stock worth $1,736,000 after purchasing an additional 4,443 shares in the last quarter. Associated Banc Corp purchased a new stake in shares of Roche in the 3rd quarter valued at about $1,740,000. Finally, North Star Asset Management Inc. acquired a new stake in shares of Roche in the 2nd quarter valued at about $1,351,000.

Roche Company Profile

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.